SINGAPORE (Reuters) – Pfizer Inc is in discussions with Singapore’s Health Sciences Authority regarding obtaining a full license application for its COVID-19 vaccine, the company said in response to a query from Reuters.
Pfizer-BioNTech’s COVID-19 vaccine has interim authorisation under the pandemic special access route in Singapore. The U.S. Food and Drug Administration granted full approval to the vaccine last month.
(Reporting by Aradhana Aravindan in Singapore; Editing by Ed Davies)
